Cost-effectiveness analysis of integrating screening and treatment of selected non-communicable diseases into HIV/AIDS treatment in Uganda.
Adult
Aged
Cost-Benefit Analysis
Delivery of Health Care, Integrated
Diabetes Mellitus
/ diagnosis
Female
HIV Infections
/ diagnosis
Humans
Hypertension
/ diagnosis
Male
Mass Screening
Middle Aged
Noncommunicable Diseases
/ economics
Prevalence
Quality-Adjusted Life Years
Risk Factors
Uganda
/ epidemiology
HIV
Uganda
antiretroviral therapy
cardiovascular diseases
diabetes
hypercholesterolaemia
hypertension
integration
non-communicable diseases
sub-Saharan Africa
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
28
09
2019
revised:
04
03
2020
accepted:
09
04
2020
entrez:
21
6
2020
pubmed:
21
6
2020
medline:
25
3
2021
Statut:
ppublish
Résumé
Despite growing enthusiasm for integrating treatment of non-communicable diseases (NCDs) into human immunodeficiency virus (HIV) care and treatment services in sub-Saharan Africa, there is little evidence on the potential health and financial consequences of such integration. We aim to study the cost-effectiveness of basic NCD-HIV integration in a Ugandan setting. We developed an epidemiologic-cost model to analyze, from the provider perspective, the cost-effectiveness of integrating hypertension, diabetes mellitus (DM) and high cholesterol screening and treatment for people living with HIV (PLWH) receiving antiretroviral therapy (ART) in Uganda. We utilized cardiovascular disease (CVD) risk estimations drawing from the previously established Globorisk model and systematic reviews; HIV and NCD risk factor prevalence from the World Health Organization's STEPwise approach to Surveillance survey and global databases; and cost data from national drug price lists, expert consultation and the literature. Averted CVD cases and corresponding disability-adjusted life years were estimated over 10 subsequent years along with incremental cost-effectiveness of the integration. Integrating services for hypertension, DM, and high cholesterol among ART patients in Uganda was associated with a mean decrease of the 10-year risk of a CVD event: from 8.2 to 6.6% in older PLWH women (absolute risk reduction of 1.6%), and from 10.7 to 9.5% in older PLWH men (absolute risk reduction of 1.2%), respectively. Integration would yield estimated net costs between $1,400 and $3,250 per disability-adjusted life year averted among older ART patients. Providing services for hypertension, DM and high cholesterol for Ugandan ART patients would reduce the overall CVD risk among these patients; it would amount to about 2.4% of national HIV/AIDS expenditure, and would present a cost-effectiveness comparable to other standalone interventions to address NCDs in low- and middle-income country settings.
Identifiants
pubmed: 32562364
doi: 10.1002/jia2.25507
pmc: PMC7305460
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25507Subventions
Organisme : FIC NIH HHS
ID : K43 TW010715
Pays : United States
Informations de copyright
© 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
Circulation. 2009 Feb 17;119(6):770-2
pubmed: 19221228
Medicine (Baltimore). 2015 Dec;94(50):e1959
pubmed: 26683910
PLoS One. 2017 Feb 24;12(2):e0171917
pubmed: 28234969
Int J Clin Pract. 2010 Aug;64(9):1173-5
pubmed: 20653794
Curr Cardiol Rep. 2004 Mar;6(2):124-9
pubmed: 14759357
JAMA. 1999 Dec 22-29;282(24):2340-6
pubmed: 10612322
AIDS. 2018 Jul 1;32 Suppl 1:S93-S105
pubmed: 29952795
AIDS. 2012 Jul 31;26 Suppl 1:S1-5
pubmed: 22713477
BMC Public Health. 2018 Jul 28;18(1):928
pubmed: 30055591
Int J Cancer. 2000 Jan 15;85(2):206-10
pubmed: 10629079
Bull World Health Organ. 2007 Nov;85(11):880-5
pubmed: 18038079
BMJ. 2012 Mar 02;344:e607
pubmed: 22389337
Eur J Cancer Prev. 2008 Nov;17(6):545-54
pubmed: 18941376
PLoS One. 2017 Aug 10;12(8):e0182951
pubmed: 28797115
BMJ. 2000 Aug 12;321(7258):405-12
pubmed: 10938048
Lancet. 2003 Nov 8;362(9395):1527-35
pubmed: 14615107
J Int AIDS Soc. 2020 Jun;23 Suppl 1:e25507
pubmed: 32562364
BMJ Glob Health. 2016 Nov 24;1(3):e000055
pubmed: 28588953
Top Antivir Med. 2014 Sep-Oct;22(4):676-9
pubmed: 25398068
AIDS. 2018 Jul 1;32 Suppl 1:S33-S42
pubmed: 29952788
Lancet Glob Health. 2015 Nov;3(11):e712-23
pubmed: 26475018
Curr Opin HIV AIDS. 2008 May;3(3):207-13
pubmed: 19372968
Clin Infect Dis. 2001 Jan;32(1):130-9
pubmed: 11118392
J Int Assoc Provid AIDS Care. 2016 Mar-Apr;15(2):164-71
pubmed: 26514630
Clin Cardiol. 2017 Mar;40(3):163-169
pubmed: 27859433
AIDS. 2018 Jul 1;32 Suppl 1:S5-S20
pubmed: 29952786
J Hum Hypertens. 2016 Jun;30(6):355-62
pubmed: 26446389
Atherosclerosis. 2011 Dec;219(2):384-9
pubmed: 21722900
J Hypertens Suppl. 1993 Dec;11(5):S268-9
pubmed: 8158378
AIDS. 2018 Jul 1;32 Suppl 1:S43-S46
pubmed: 29952789
Lancet Diabetes Endocrinol. 2015 May;3(5):339-55
pubmed: 25819778
Int J Gynaecol Obstet. 2016 Mar;132(3):252-8
pubmed: 26868062
J Stroke Cerebrovasc Dis. 2017 May;26(5):1154-1160
pubmed: 28262563
Circulation. 2013 Apr 9;127(14):1493-502, 1502e1-8
pubmed: 23481623
PLoS One. 2016 Jun 27;11(6):e0157925
pubmed: 27348310
AIDS. 2018 Jul 1;32 Suppl 1:S83-S92
pubmed: 29952794
Int J Cardiol. 2015 Nov 15;199:307-18
pubmed: 26241636